Abstract Library

#4292 Predictors based on the radiologic characteristics for aggressiveness of small (＜20 mm) non-functioning pancreatic neuroendocrine tumours

Introduction: The management of small non-functioning PNETs remains controversial due to their heterogeneity. Results from some retrospective surgical reports found that a subset of small NF-PNETs may show aggressive behaviour, for which surgical resection is recommended.

Conference:

Presenting Author: Shu-Jie R

Authors: Ren S, Fan Y, Tan C, Wang X, Tan Q,

Keywords: small pancreatic neuroendocrine tumour, high-risk factor, radiologic characteristics, tumour marker, prognostic factor,

#4193 Pivotal role of the multidisciplinary tumor board on the management of neuroendocrine neoplasms – Impact of MTB decisions in an ENETS Center of Excellence

Introduction: Multidisciplinary Tumor Board (MTB) meetings are a valuable tool to improve the management of solid tumors. Yet, few evidences regarding the real-world impact of Neuroendocrine Neoplasm (NEN)-dedicated MTBs are available.

Conference:

Presenting Author:

Authors: Maratta M, Vitale A, Occhipinti D, Raia S, Menotti S,

Keywords: multidisciplinary tumor board, neuroendocrine cancer, disease management, patient care,

#3958 Treatment strategy for pancreatic NETs smaller than 2 cm should be based on the diagnosis of malignancy as well – New treatment strategy for small pancreatic NETs

Introduction: There are still many unclear issues regarding the treatment of non-functioning small (≤20 mm) pancreatic neuroendocrine neoplasms (pNENs).

Conference:

Presenting Author: Hijioka S

Authors: Hijioka S, Yamashige D, Esaki M, Honda G, Masui T,

Keywords: small pancreatic neuroendocrine neoplasm, tumor size, grading, treatment strategy, Japanese cohort,

#3813 First report of the phase I LuPARP trial assessing 177Lu-DOTATATE in combination with the PARP inhibitor olaparib in patients with somatostatin positive tumors

Introduction: Patients with metastatic somatostatin receptor positive tumors can be treated with peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE. However, all patients do not respond sufficiently, and further treatment optimization is highly warranted. We hypothesize that the tumoricidal effect could be increased by adding a PARP inhibitor which will decrease the ability of the tumor cells to repair DNA-damage, making them more sensitive to radiation and increase the probability of tumor cell death.

Conference:

Presenting Author: Hallqvist A

Authors: Hallqvist A, Sjögren M, Krantz T, Holgersson K, Svensson J,

Keywords: PRRT, 177Lu-DOTATATE, olaparib,

#3482 PANDORA-2 protocol - Intervention study to improve quality of life in patients with small (≤2 cm) non-functional pancreatic neuroendocrine tumors

Introduction: Current guidelines changed the treatment strategy for small (≤2cm) non-functioning pancreatic neuroendocrine tumors (NF-pNET) from tumor resection to an active surveillance strategy. The previous PANDORA-1 (2021) study showed excellent clinical outcomes after a median follow-up of 17 months, where 89% of patients had pNETs without any tumor growth and only 3% of patients had tumor growth leading to a resection. Despite these results, the quality of life (QoL) was decreased at baseline and during follow-up. Furthermore, there was suboptimal adherence to the advised surveillance protocol.

Conference:

Presenting Author: Chen J

Authors: Chen J, Heidsma C, Engelsman A, Nieveen van Dijkum E,

Keywords: neuroendocrine, pancreatic, quality of life, ≤2 cm, non-functional, protocol,